Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00174187 |
Condition | Intervention | Phase |
---|---|---|
Endocrine System Diseases |
Drug: Somatropin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety. |
Enrollment: | 30 |
Study Start Date: | September 2000 |
Estimated Study Completion Date: | December 2015 |
Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Somatropin: Experimental |
Drug: Somatropin
liquide, daily, until final height Dosage: 0,46 mg/kg/week
|
Ages Eligible for Study: | 11 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | 307-MET-9002-0009, A6281016 |
Study First Received: | September 9, 2005 |
Last Updated: | December 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00174187 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
Neoplasm Metastasis Endocrine System Diseases Endocrinopathy |